Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers is a research paper published in Cells (2024). On theSindex it has a DataRank of 0.434. It has been cited 17 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.434
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →VA Merit Review grants (S.K.B. and S.B.) VA Research Career Award Fund (S.K.B.)
Grant: 1P20 GM109024
NIGMS NIH HHS
Grant: 5P20GM109024-05
BLRD VA
Grant: I01 BX001989
NIGMS NIH HHS
Grant: P20 GM109024
BLRD VA
Grant: I01 BX001002
BLRD VA
Grant: I01 BX006279
BLRD VA
Grant: IK6 BX005769
BLRD VA
Grant: I01 BX004497
National Institutes of Health
Grant: 5P20GM109024-04
Center for Diagnostic and Therapeutic Strategies in Pancreatic Cancer
FWCI
2.75
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals